The Supralimus® sirolimus-eluting stent

Expert Review of Medical Devices

Volumn 10, Issue 3, 2013, Pages 295-300

  Lemos, Pedro A ^a,b   Bienert, Igor ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratory of Pharmacology   (Brazil)

Author keywords

angioplasty; atherosclerosis; biodegradable; coronary; restenosis; stent; thrombosis

Indexed keywords

ANGIOPLASTY; ATHEROSCLEROSIS; BIODEGRADABLE; CORONARY; RESTENOSIS; STENT; THROMBOSIS;

BIOMEDICAL ENGINEERING; BLOOD VESSELS; DISEASES; PLASTIC COATINGS; THICKNESS MEASUREMENT;

STENTS;

PACLITAXEL; RAPAMYCIN; SUPRALIMUS; UNCLASSIFIED DRUG;

ARTICLE; BARE METAL STENT; CORONARY STENT; DEGRADATION; DEVICE SAFETY; DRUG BLOOD LEVEL; DRUG ELUTING STENT; DRUG SOLUBILITY; DRUG STRUCTURE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; NEOINTIMA; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS; SUSTAINED DRUG RELEASE; ANIMAL; CLINICAL TRIAL (TOPIC); EUROPE; EVALUATION STUDY; REVIEW; UNITED STATES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; EUROPE; EVALUATION STUDIES AS TOPIC; HUMANS; SIROLIMUS; UNITED STATES;

EID: 84877897256     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.12.91     Document Type: Article

References (21)

1. Faxon DP, Creager MA, Smith SC Jr et al.; American Heart Association. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 109(21), 2595-2604 (2004).
2. Ong AT, Daemen J, van Hout BA et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Eur. Heart J. 27(24), 2996-3003 (2006).
3. Lemos PA, Mercado N, van Domburg RT, Kuntz RE, O'Neill WW, Serruys PW. Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 110(20), 3199-3205 (2004).
4. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxeleluting coronary stents. N. Engl. J. Med. 356(10), 998-1008 (2007).
5. van Domburg RT, Lemos PA, Takkenberg JJ et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur. Heart J. 26(7), 675-681 (2005).
6. Baran KW, Lasala JM, Cox DA et al.; ARRIVE Investigators. A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. EuroIntervention 6(8), 949-954 (2011).
7. Lima KM, Rodrigues Jr JM. Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Braz. J. Med. Biol. Res. 32(2), 171-180 (1999).
8. Zhou ZH, Liu XP, Liu QQ, Liu LH. Morphology, molecular mass changes, and degradation mechanism of poly-llactide in phosphate-buffered solution. Poly.-Plastics Technol. Eng. 47, 115-120 (2009).
9. Hu X, Shen H, Yang F, Bei J, Wang S. Preparation and cell affinity of microtubular orientation-structured PLGA(70/30) blood vessel scaffold. Biomaterials 29(21), 3128-3136 (2008).
10. Liu X, Won Y, Ma PX. Surface modification of interconnected porous scaffolds. J. Biomed. Mater. Res. A 74(1), 84-91 (2005).
11. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21(23), 2335-2346 (2000).
12. Wykrzykowska J, Serruys P, Buszman P et al. The three-year follow-up of the randomised 'all-comers' trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). EuroIntervention 7(7), 789-795 (2011).
13. Xu J, Wang J, Dong X, Liu G, Yu W. Preparation of PVP/PLLA ultrafine blend fibers by electrospinning. Int. J. Chem. 3(4), 57-60 (2011).
14. Chin WW, Heng PW, Thong PS et al. Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. Eur. J. Pharm. Biopharm. 69(3), 1083-1093 (2008).
15. Thakkar A, Raval A, Mandal R et al. Development and evaluation of drug eluting stent having biphasic release from a single layer of biodegradable polymer. J. Med. Devices 7(1), 011005 (2013).
16. Dani S, Kukreja N, Parikh P et al. Biodegradable-polymer-based, sirolimuseluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention 4(1), 59-63 (2008).
17. Costa JR Jr, Abizaid A, Machado B et al. Supralimus bioabsorbable-polymer sirolimus-eluting stent technology in patients with acute coronary syndrome: two-year results of the prospective, multicenter, E-SERIES registry. J. Am. Coll. Cardiol. 55, A208 (2010).
18. Lemos PA, Moulin B, Perin MA et al.; PAINT study. Rationale and design for the PAINT randomized trial. Arq. Bras. Cardiol. 93(6), 547-553, 590-597 (2009).
19. Lemos PA, Moulin B, Perin MA et al.; PAINT trial investigators. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter. Cardiovasc. Interv. 74(5), 665-673 (2009).
20. Lemos PA, Moulin B, Perin MA et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. EuroIntervention 8(1), 117-119 (2012).
21. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115(11), 1433-1439; discussion 1439 (2007).